Advertisement

Molecular and Cellular Functions of CTLA-4

  • Samya Van CoillieEmail author
  • Bartosz Wiernicki
  • Jie XuEmail author
Chapter
  • 229 Downloads
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1248)

Abstract

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is an inhibitory receptor belonging to the CD28 immunoglobulin subfamily, expressed primarily by T-cells. Its ligands, CD80 and CD86, are typically found on the surface of antigen-presenting cells and can either bind CD28 or CTLA-4, resulting in a costimulatory or a co-inhibitory response, respectively. Because of its dampening effect, CTLA-4 is a crucial regulator of T-cell homeostasis and self-tolerance. The mechanisms by which CTLA-4 exerts its inhibitory function can be categorized as either cell-intrinsic (affects the CTLA-4 expressing T-cell) or cell-extrinsic (affects secondary cells). Research from the last decade has shown that CTLA-4 mainly acts in a cell-extrinsic manner via its competition with CD28, CTLA-4-mediated trans-endocytosis of CD80 and CD86, and its direct tolerogenic effects on the interacting cell. Nonetheless, intrinsic CTLA-4 signaling has been implicated in T-cell motility and the regulation of CTLA-4 its subcellular localization amongst others. CTLA-4 is well recognized as a key immune checkpoint and has gained significant momentum as a therapeutic target in the field of autoimmunity and cancer. In this chapter, we describe the role of costimulation in immune response induction as well as the main mechanisms by which CTLA-4 can inhibit this process.

Keywords

CTLA-4 CD28 CD80 CD86 Immune tolerance 

References

  1. Aaes TL et al (2016) Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep 15(2):274–287.  https://doi.org/10.1016/J.CELREP.2016.03.037. Cell Press
  2. Abrams JR et al (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Investig 103(9):1243–1252.  https://doi.org/10.1172/JCI5857CrossRefPubMedGoogle Scholar
  3. Acuto O, Michel F (2003) CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 3(12):939–951.  https://doi.org/10.1038/nri1248. Nature Publishing Group
  4. Adams AB, Ford ML, Larsen CP (2016) Costimulation blockade in autoimmunity and transplantation: the CD28 pathway HHS public access. J Immunol 197(6):2045–2050.  https://doi.org/10.4049/jimmunol.1601135CrossRefPubMedPubMedCentralGoogle Scholar
  5. Alissafi T et al (2017) Tregs restrain dendritic cell autophagy to ameliorate autoimmunity. J Clin Investig 127(7):2789–2804.  https://doi.org/10.1172/jci92079
  6. Apetoh L et al (2007) The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220(1):47–59.  https://doi.org/10.1111/j.1600-065X.2007.00573.xCrossRefPubMedGoogle Scholar
  7. Appleman LJ, Boussiotis VA (2003) T cell anergy and costimulation. Immunol Rev 192(1):161–180.  https://doi.org/10.1034/j.1600-065x.2003.00009.x. Wiley (10.1111)
  8. Arra A et al (2017) The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs. Oncoimmunology 6(2):e1273300.  https://doi.org/10.1080/2162402x.2016.1273300. Taylor & Francis
  9. Baroja ML et al (2002) Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A. J Immunol 168(10):5070–5078.  https://doi.org/10.4049/jimmunol.168.10.5070CrossRefPubMedGoogle Scholar
  10. Barquín-García A et al (2019) New oncologic emergencies: what is there to know about immunotherapy and its potential side effects? Eur J Intern Med.  https://doi.org/10.1016/j.ejim.2019.05.020CrossRefPubMedGoogle Scholar
  11. Bochkov VN et al (2010) Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal 12(8):1009–1059.  https://doi.org/10.1089/ars.2009.2597CrossRefPubMedPubMedCentralGoogle Scholar
  12. Boomer JS, Green JM (2010) An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol 2(8):a002436.  https://doi.org/10.1101/cshperspect.a002436. Cold Spring Harbor Laboratory Press
  13. Borrie AE, Maleki Vareki S (2018) T lymphocyte-based cancer immunotherapeutics. Int Rev Cell Mol Biol 341:201–276.  https://doi.org/10.1016/BS.IRCMB.2018.05.010. Academic
  14. Bourque J, Hawiger D (2018) Immunomodulatory bonds of the partnership between dendritic cells and T cells. Crit Rev Immunol 38(5):379–401.  https://doi.org/10.1615/critrevimmunol.2018026790. NIH Public Access
  15. Bretscher PA (1999) A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci 96(1):185–190.  https://doi.org/10.1073/pnas.96.1.185CrossRefPubMedGoogle Scholar
  16. Bretscher P, Cohn M (1970) A theory of self-nonself discrimination 169(1964)Google Scholar
  17. Brunet J-F et al (1987) A new member of the immunoglobulin superfamily—CTLA-4. Nature 328(6127):267–270.  https://doi.org/10.1038/328267a0CrossRefPubMedGoogle Scholar
  18. Buchbinder EI, Desai A (2015) CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition.  https://doi.org/10.1097/COC.0000000000000239
  19. Calvo CR, Amsen D, Kruisbeek AM (1997) Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated kinase (ERK) and Jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor zeta and ZAP70. J Exp Med 186(10):1645–1653.  https://doi.org/10.1084/jem.186.10.1645. Rockefeller University Press
  20. Cao W et al (2014) Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol 192(6):2920–2931.  https://doi.org/10.4049/jimmunol.1302801CrossRefPubMedCentralGoogle Scholar
  21. Carreno BM, Collins M (2002) The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 20:29–53.  https://doi.org/10.1146/annurev.immunol.20.091101.091806CrossRefPubMedGoogle Scholar
  22. Chambers CA et al (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19(1):565–594.  https://doi.org/10.1146/annurev.immunol.19.1.565. Annual Reviews 4139 El Camino Way, P.O. Box 10139, Palo Alto, CA 94303-0139, USA
  23. Chambers CA, Allison JP (1997) ‘Co-stimulation in T cell responses. Curr Opin Immunol 9(3):396–404.  https://doi.org/10.1016/S0952-7915(97)80087-8. Elsevier Current Trends
  24. Chen L, Flies DB (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13(4):227–242.  https://doi.org/10.1038/nri3405CrossRefPubMedPubMedCentralGoogle Scholar
  25. Collins AV et al (2002) The interaction properties of costimulatory molecules revisited. Immunity 17(2):201–210.  https://doi.org/10.1016/S1074-7613(02)00362-XCrossRefPubMedGoogle Scholar
  26. Coyle AJ et al (2000) The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 13(1):95–105.  https://doi.org/10.1016/S1074-7613(00)00011-X. Cell Press
  27. Crimeen-Irwin B et al (2005) Failure of immune homeostasis – the consequences of under and over reactivity. Curr Drug Targets. Immune, Endocr Metab Disord 5(4):413–422. http://www.ncbi.nlm.nih.gov/pubmed/16375694. Accessed 21 July 2019
  28. Croft M (2003) Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev 14(3–4):265–273.  https://doi.org/10.1016/S1359-6101(03)00025-X. Pergamon
  29. Dixon SJ et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell.  https://doi.org/10.1016/j.cell.2012.03.042CrossRefPubMedPubMedCentralGoogle Scholar
  30. Dower NA et al (2000) RasGRP is essential for mouse thymocyte differentiation and TCR signaling. Nat Immunol 1(4):317–321.  https://doi.org/10.1038/79766CrossRefPubMedGoogle Scholar
  31. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22(1):329–360.  https://doi.org/10.1146/annurev.immunol.22.012703.104803. Annual Reviews
  32. Elgueta R et al (2009) Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229(1):152–172.  https://doi.org/10.1111/j.1600-065x.2009.00782.x. NIH Public Access
  33. Engelhardt JJ, Sullivan TJ, Allison JP (2006) CTLA-4 overexpression Inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol 177:1052–1061.  https://doi.org/10.4049/jimmunol.177.2.1052CrossRefPubMedGoogle Scholar
  34. Esensten JH et al (2016) CD28 costimulation: from mechanism to therapy. Immunity 44(5):973–988.  https://doi.org/10.1016/j.immuni.2016.04.020CrossRefPubMedPubMedCentralGoogle Scholar
  35. Fallarino F et al (2003) Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4(12):1206–1212.  https://doi.org/10.1038/ni1003. Nature Publishing Group
  36. Flies DB et al (2014) Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity. J Clin Investig 124(5):1966–1975.  https://doi.org/10.1172/JCI74589.American Society for Clinical Investigation
  37. Freeman GJ (2004) Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med 178:2185–2192.  https://doi.org/10.1084/jem.178.6.2185CrossRefGoogle Scholar
  38. Galluzzi L et al (2018) Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ.  https://doi.org/10.1038/s41418-017-0012-4CrossRefPubMedPubMedCentralGoogle Scholar
  39. Gao Q et al (2019) A cycle involving HMGB1, IFN-γ and dendritic cells plays a putative role in anti-tumor immunity. Cell Immunol 343:103850.  https://doi.org/10.1016/J.CELLIMM.2018.08.011. Academic
  40. Gavrieli M, Murphy KM (2006) ‘Association of Grb-2 and PI3K p85 with phosphotyrosile peptides derived from BTLA. Biochem Biophys Res Commun 345(4):1440–1445.  https://doi.org/10.1016/J.BBRC.2006.05.036. Academic
  41. Ghahremanloo A et al (2019) Recent advances in the clinical development of immune checkpoint blockade therapy. Cell Oncol.  https://doi.org/10.1007/s13402-019-00456-wCrossRefGoogle Scholar
  42. Golden EB, Apetoh L (2015) Radiotherapy and immunogenic cell death. Semin Radiat Oncol 25(1):11–17.  https://doi.org/10.1016/j.semradonc.2014.07.005. Elsevier
  43. Haining WN, Weiss SA (2018) c-Maf in CD4+ T cells: it’s all about context. Nat Immunol 19(5):429–431.  https://doi.org/10.1038/s41590-018-0087-1. Nature Publishing Group
  44. Halpert MM et al (2016) Dendritic cell-secreted cytotoxic T-lymphocyte-associated protein-4 regulates the T-cell response by downmodulating bystander surface B7. Stem Cells Dev 25(10):774–787.  https://doi.org/10.1089/scd.2016.0009
  45. Hangauer MJ et al (2017) Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551(7679):247–250.  https://doi.org/10.1038/nature24297. Nature Publishing Group
  46. Hassannia B et al (2018) Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. J Clin Investig 128:3341–3355.  https://doi.org/10.1172/JCI99032CrossRefPubMedGoogle Scholar
  47. Hirahara K, Nakayama T (2016) CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. Int Immunol 28(4):163–171.  https://doi.org/10.1093/intimm/dxw006. Narnia
  48. Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723.  https://doi.org/10.1056/NEJMoa1003466CrossRefPubMedPubMedCentralGoogle Scholar
  49. Hu H, Rudd CE, Schneider H (2001) Src kinases Fyn and Lck facilitate the accumulation of phosphorylated CTLA-4 and its association with PI-3 kinase in intracellular compartments of T-cells. Biochem Biophys Res Commun 288(3):573–578.  https://doi.org/10.1006/BBRC.2001.5814. Academic
  50. Hutloff A et al (1999) ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397(6716):263–266.  https://doi.org/10.1038/16717. Nature Publishing Group
  51. Ikemizu S et al (2000) Structure and dimerization of a soluble form of B7-1 transfecting B7-1 into murine tumors (Chen et al or from using anti-CTLA-4 antibodies to block CTLA-4 interactions with B7-1 and, immunity. Townsend and Allison). https://www.cell.com/action/showPdf?pii=S1074-7613%2800%2980158-2. Accessed 11 July 2019
  52. Isakov N, Altman A (2002) Protein kinase Cθ in T cell activation. Annu Rev Immunol 20(1):761–794.  https://doi.org/10.1146/annurev.immunol.20.100301.064807. Annual Reviews 4139 El Camino Way, P.O. Box 10139, Palo Alto, CA 94303-0139, USA
  53. Jain N et al (2010) Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci 107(4):1524–1528.  https://doi.org/10.1073/pnas.0910341107CrossRefPubMedGoogle Scholar
  54. Jenkins MK et al (1987) T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol Rev 95:113–135. http://www.ncbi.nlm.nih.gov/pubmed/2437012. Accessed 12 May 2019
  55. June CH et al (1987) T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol 7(12):4472–4481. American Society for Microbiology (ASM).  https://doi.org/10.1128/mcb.7.12.4472
  56. Jung M et al (2019) Iron as a central player and promising target in cancer progression. Int J Mol Sci 20(2):1–18.  https://doi.org/10.3390/ijms20020273CrossRefGoogle Scholar
  57. Kaur S, Qureshi OS, Sansom DM (2013) Comparison of the intracellular trafficking itinerary of CTLA-4 orthologues. PLoS ONE 8(4):e60903.  https://doi.org/10.1371/journal.pone.0060903. Boudinot P (ed) Public Library of Science
  58. Kepp O et al (2014) Consensus guidelines for the detection of immunogenic cell death. OncoImmunology 3(9):1–19.  https://doi.org/10.4161/21624011.2014.955691CrossRefGoogle Scholar
  59. Khailaie S et al (2018) Characterization of CTLA4 trafficking and implications for its function. Biophys J 115(7):1330–1343.  https://doi.org/10.1016/J.BPJ.2018.08.020. Cell Press
  60. Korman AJ, Peggs KS, Allison JP (2006) Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297–339.  https://doi.org/10.1016/s0065-2776(06)90008-x
  61. Kroczek RA, Mages HW, Hutloff A (2004) Emerging paradigms of T-cell co-stimulation. Curr Opin Immunol 16(3):321–327.  https://doi.org/10.1016/j.coi.2004.03.002CrossRefPubMedGoogle Scholar
  62. Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182(2):459–465. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192127/pdf/je1822459.pdf. Accessed 10 June 2019
  63. Krummey SM et al (2014) High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept. Am J Transplant: Off J Am Soc Transplant Am Soc Transpl Surg 14(3):607–614. http://www.ncbi.nlm.nih.gov/pubmed/24730049. Accessed 17 Sept 2019. NIH Public Access
  64. Kuemmerle-Deschner JB, Benseler SM (2008) Abatacept in difficult-to-treat juvenile idiopathic arthritis. Targets Ther, Biologics, pp 865–874Google Scholar
  65. Kumar P, Bhattacharya P, Prabhakar BS (2018) A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. J Autoimmun 95:77–99.  https://doi.org/10.1016/J.JAUT.2018.08.007. Academic
  66. Lafferty K, Cunningham A (1975) A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 53(1):27–42.  https://doi.org/10.1038/icb.1975.3. Wiley (10.1111)
  67. Lafferty KJ, Woolnough J (1977) The origin and mechanism of the allograft reaction. Immunol Rev 35(1):231–262.  https://doi.org/10.1111/j.1600-065x.1977.tb00241.x. Wiley (10.1111)
  68. Lafferty KJ et al (1978) Immunological induction of T lymphocytes: role of antigen and the lymphocyte costimulator. Blood Cells 4(3):395–406. http://www.ncbi.nlm.nih.gov/pubmed/95670. Accessed 9 June 2019
  69. Laurent S et al (2010) CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Hum Immunol 71(10):934–941.  https://doi.org/10.1016/j.humimm.2010.07.007
  70. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734–1736.  https://doi.org/10.1126/science.271.5256.1734CrossRefPubMedPubMedCentralGoogle Scholar
  71. Lee K-M et al (1998) Molecular basis of T cell inactivation by CTLA-4. Science 282(5397):2263–2266.  https://doi.org/10.1126/science.282.5397.2263. American Association for the Advancement of Science
  72. Lindsten T et al (1993) Characterization of CTLA-4 structure and expression on human T cells. J Immunol 151(7)3489–3799. http://www.jimmunol.org/content/151/7/3489. Accessed 13 July 2019. Baltimore, Md.: 1950
  73. Lingel H et al (2017) CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation. Cell Death Differ 24(10):1739–1749.  https://doi.org/10.1038/cdd.2017.102. Nature Publishing Group
  74. Linsley PS, Clark EA, Ledbetter JA (1990) T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci 87(13):5031–5035.  https://doi.org/10.1073/pnas.87.13.5031
  75. Linsley PS et al (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174(3):561–569.  https://doi.org/10.1084/jem.174.3.561. The Rockefeller University Press
  76. Linsley PS et al (1992) Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257(5071):792–795.  https://doi.org/10.1126/science.1496399. American Association for the Advancement of Science, New York, N.Y.
  77. Linsley PS et al (1995) Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). J Biol Chem 270(25):15417–15424.  https://doi.org/10.1074/jbc.270.25.15417CrossRefPubMedGoogle Scholar
  78. Mages HW et al (2000) ‘Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand. Eur J Immunol 30(4):1040–1047.  https://doi.org/10.1002/(SICI)1521-4141(200004)30:4%3c1040:AID-IMMU1040%3e3.0.CO;2-6. Wiley
  79. Magistrelli G et al (1999) A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 29(11):3596–3602.  https://doi.org/10.1002/(SICI)1521-4141(199911)29:11%3c3596:AID-IMMU3596%3e3.0.CO;2-YCrossRefPubMedGoogle Scholar
  80. Mak TW et al (2014) Primer to the immune response. https://www.worldcat.org/title/primer-to-the-immune-response/oclc/900161289. Accessed 3 Sept 2019
  81. Marengère LE et al (1996) Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 272(5265):1170–1173.  https://doi.org/10.1126/science.272.5265.1170. New York, N.Y.
  82. Matheu MP et al (2015) Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming. Nat Commun 6:6219.  https://doi.org/10.1038/ncomms7219
  83. Mease PJ et al (2017) Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 76(9):1550–1558.  https://doi.org/10.1136/annrheumdis-2016-210724CrossRefPubMedPubMedCentralGoogle Scholar
  84. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480(7378):480–489.  https://doi.org/10.1038/nature10673CrossRefPubMedPubMedCentralGoogle Scholar
  85. Metzler WJ et al (1997) Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28. Nat Struct Biol 4(7):527–531. http://www.ncbi.nlm.nih.gov/pubmed/9228944. Accessed 14 July 2019
  86. Mir MA (2015) Introduction to costimulation and costimulatory molecules. Developing Costimulatory Molecules for Immunotherapy of Diseases.  https://doi.org/10.1016/B978-0-12-802585-7.00001-7CrossRefGoogle Scholar
  87. Moreland LW et al (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46(6):1470–1479.  https://doi.org/10.1002/art.10294CrossRefPubMedGoogle Scholar
  88. Motzer RJ et al (2018) Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. New Engl J Med 378(14):1277–1290.  https://doi.org/10.1056/NEJMoa1712126. Massachusetts Medical Society
  89. Mueller DL (1989) Do tolerant T cells exist? Nature 339(6225):513–514.  https://doi.org/10.1038/339513a0. Nature Publishing Group
  90. Munn DH, Sharma MD, Mellor AL (2004) Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 172(7):4100–4110.  https://doi.org/10.4049/jimmunol.172.7.4100. Baltimore, Md.: 1950
  91. Murphy K, Weaver C (2017) Janeway’s immunobiology, 9th ednGoogle Scholar
  92. Murphy KM, Nelson CA, Šedý JR (2006) Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol 6(9):671–681.  https://doi.org/10.1038/nri1917. Nature Publishing Group
  93. NIH US National Library of Medicine (2019) Home - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/home. Accessed 24 July 2019
  94. O’Donnell JS, Teng MWL, Smyth MJ (2019) Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 16(3):151–167.  https://doi.org/10.1038/s41571-018-0142-8CrossRefPubMedGoogle Scholar
  95. Obeid M et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54–61.  https://doi.org/10.1038/nm1523CrossRefPubMedGoogle Scholar
  96. Oh-hora M, Rao A (2009) The calcium/NFAT pathway: role in development and function of regulatory T cells. Microbes Infect 11(5):612–619.  https://doi.org/10.1016/j.micinf.2009.04.008. NIH Public Access
  97. Oskolkova OV et al (2010) Oxidized phospholipids are more potent antagonists of lipopolysaccharide than inducers of inflammation. J Immunol 185(12):7706–7712.  https://doi.org/10.4049/jimmunol.0903594CrossRefPubMedGoogle Scholar
  98. Ovcinnikovs V et al (2019) CTLA-4–mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells. Sci Immunol 4(35):eaaw0902.  https://doi.org/10.1126/sciimmunol.aaw0902
  99. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 252–264.  https://doi.org/10.1038/nrc3239
  100. Parry RV et al (2005) CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25(21):9543–9553.  https://doi.org/10.1128/mcb.25.21.9543-9553.2005. American Society for Microbiology (ASM)
  101. Pentcheva-Hoang T et al (2004) B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21(3):401–413.  https://doi.org/10.1016/J.IMMUNI.2004.06.017. Cell Press
  102. Poleszczuk J, Enderling H (2018) The optimal radiation dose to induce robust systemic anti-tumor immunity. Int J Mol Sci 19(11).  https://doi.org/10.3390/ijms19113377
  103. Qureshi OS et al (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332(6029):600–603.  https://doi.org/10.1126/science.1202947CrossRefPubMedPubMedCentralGoogle Scholar
  104. Rao A, Luo C, Hogan PG (2002) Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 15(1):707–747.  https://doi.org/10.1146/annurev.immunol.15.1.707CrossRefGoogle Scholar
  105. Ravetch JV, Lanier LL (2000) Immune inhibitory receptors. Science 290(5489):84–89.  https://doi.org/10.1126/science.290.5489.84. American Association for the Advancement of Science, New York, N.Y.
  106. Read S, Malmström V, Powrie F (2000) Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192(2):295–302.  https://doi.org/10.1084/jem.192.2.295. Rockefeller University Press
  107. Ren J et al (2017) The RIP3-RIP1-NF-kB signaling axis is dispensable for necroptotic cells to elicit cross-priming of CD8+ T cells. Cell Mol Immunol 14(7):639–642.  https://doi.org/10.1038/cmi.2017.31. Nature Publishing Group
  108. Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: a moving target in immunotherapy. Blood 131(1):58–67.  https://doi.org/10.1182/blood-2017-06-741033. Europe PMC Funders
  109. Rudd CE (2008) The reverse stop-signal model for CTLA4 function. Nat Rev Immunol 8:153–160. www.nature.com/reviews/immunol. Accessed 26 July 2019
  110. Rudd CE, Schneider H (2003) Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol 3(7):544–556.  https://doi.org/10.1038/nri1131. Nature Publishing Group
  111. Rudd CE, Taylor A, Schneider H (2009) CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 229(1):12–26.  https://doi.org/10.1111/j.1600-065x.2009.00770.x. Europe PMC Funders
  112. Ruperto N et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. The Lancet 372(9636):383–391.  https://doi.org/10.1016/S0140-6736(08)60998-8CrossRefGoogle Scholar
  113. Saito T, Yokosuka T, Hashimoto-Tane A (2010) Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters. FEBS Lett 584(24):4865–4871.  https://doi.org/10.1016/j.febslet.2010.11.036. Wiley
  114. Sakaguchi S et al (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151–1164. http://www.jimmunol.org/content/155/3/1151. Accessed 21 July 2019
  115. Sanchez-Lockhart M et al (2014) T cell receptor signaling can directly enhance the avidity of CD28 ligand binding. PLoS ONE 9(2):89263.  https://doi.org/10.1371/journal.pone.0089263CrossRefGoogle Scholar
  116. Saverino D et al (2010) The soluble CTLA-4 receptor and its role in autoimmune diseases: an update. Autoimmun Highlights 1(2):73–81.  https://doi.org/10.1007/s13317-010-0011-7CrossRefGoogle Scholar
  117. Schneider H, Rudd CE (2000) Tyrosine phosphatase SHP-2 binding to CTLA-4: absence of direct YVKM/YFIP motif recognition. Biochem Biophys Res Commun 269(1):279–283.  https://doi.org/10.1006/BBRC.2000.2234. Academic
  118. Schneider H et al (1999) Cytolytic T lymphocyte-associated antigen-4 and the TCR zeta/CD3 complex, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2. J Immunol 163(4):1868–1879. http://www.ncbi.nlm.nih.gov/pubmed/10438921. Accessed 12 July 2019. Baltimore, Md.: 1950
  119. Schneider H et al (2001) A regulatory role for cytoplasmic YVKM motif in CTLA-4 inhibition of TCR signaling. Eur J Immunol 31(7):2042–2050.  https://doi.org/10.1002/1521-4141(200107)31:7%3c2042:AID-IMMU2042%3e3.0.CO;2-D. Wiley
  120. Schneider H et al (2006) Reversal of the TCR stop signal by CTLA-4. Science 313(5795):1972–1975.  https://doi.org/10.1126/science.1131078CrossRefPubMedGoogle Scholar
  121. Schneider H, Valk E et al (2008a) CTLA-4 activation of phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB/AKT) sustains T-cell anergy without cell death. PLoS ONE 3(12):e3842.  https://doi.org/10.1371/journal.pone.0003842. Wölfl S (ed) Public Library of Science
  122. Schneider H, Smith X et al (2008b) CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization. Eur J Immunol 38(1):40–47.  https://doi.org/10.1002/eji.200737423. Wiley
  123. Schubert D et al (2014) Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations Europe PMC funders group. Nat Med 20(12):1410–1416.  https://doi.org/10.1038/nm.3746CrossRefPubMedPubMedCentralGoogle Scholar
  124. Schwartz RH (1990) A cell culture model for T lymphocyte clonal anergy. Science 248(4961):1349–1356. http://www.ncbi.nlm.nih.gov/pubmed/2113314. Accessed 12 May 2019. New York, N.Y.
  125. Sedy JR et al (2005) B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 6(1):90–98.  https://doi.org/10.1038/ni1144. Nature Publishing Group
  126. Shapiro VS et al (1997) CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites. Mol Cell Biol 17(7):4051–4058.  https://doi.org/10.1128/mcb.17.7.4051. American Society for Microbiology (ASM)
  127. Sharpe AH, Freeman GJ (2002) The B7-CD28 superfamily. Nat Rev Immunol 2:116.  https://doi.org/10.1038/nri727
  128. Shinohara T et al (1994) Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics 23(3):704–706.  https://doi.org/10.1006/GENO.1994.1562. Academic
  129. Shiratori T et al (1997) Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity 6(5):583–589.  https://doi.org/10.1016/S1074-7613(00)80346-5CrossRefPubMedGoogle Scholar
  130. Simons KH et al (2019) T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword. Nat Rev Cardiol 16(6):325–343.  https://doi.org/10.1038/s41569-019-0164-7
  131. Sinclair NRSC (1990) Commentary I: how many signals are enough? Cell Immunol 130(1):204–212.  https://doi.org/10.1016/0008-8749(90)90174-P. Academic
  132. Sinclair NRSC, Anderson CC (1996) Co-stimulation and co-inhibition: Equal partners in regulation. Scand J Immunol 597–603.  https://doi.org/10.1046/j.1365-3083.1996.d01-267.x. Wiley (10.1111)
  133. Stephen B, Hajjar J (2018) Overview of basic immunology and translational relevance for clinical investigators. Adv Exp Med Biol 995:1–41.  https://doi.org/10.1007/978-3-030-02505-2_1. Springer, Cham
  134. Sturgill ER, Redmond WL (2017) TNFR agonists: a review of current biologics targeting OX40, 4-1BB, CD27, and GITR. Am J Hematol/Oncol 13(11):4–15. www.ajho.com. Accessed 10 June 2019
  135. Sugár IP et al (2017) Multiscale modeling of complex formation and CD80 depletion during immune synapse development. Biophys J Biophys Soc 112(5):997–1009.  https://doi.org/10.1016/j.bpj.2016.12.052
  136. Sun H et al (2014) Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4 HHS public access. Science 345(6204):1623–1627.  https://doi.org/10.1126/science.1255904CrossRefGoogle Scholar
  137. Takahashi T et al (2000a) Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192(2):303–310.  https://doi.org/10.1084/jem.192.2.303. Rockefeller University Press
  138. Takahashi T et al (2000b) Immunologic self-tolerance maintained by CD25+CD4+regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192(2):303–309.  https://doi.org/10.1084/jem.192.2.303
  139. Teft WA, Kirchhof MG, Madrenas J (2006) A molecular perspective of CTLA-4 function.  https://doi.org/10.1146/annurev.immunol.24.021605.090535
  140. Thompson Emma L, Masteller CB, Chuang E, Mullen AC (2000) Structural analysis of CTLA-4 function in vivo. J Immunol 164:5319–5327.  https://doi.org/10.4049/jimmunol.164.10.5319CrossRefGoogle Scholar
  141. Tivol EA et al (1995a) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5):541–547.  https://doi.org/10.1016/1074-7613(95)90125-6
  142. Tivol EA et al (1995b) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. https://www.cell.com/immunity/pdf/1074-7613(95)90125-6.pdf. Accessed 10 June 2019
  143. Topalian SL, Weiner GJ, Pardoll DM (2011) Cancer immunotherapy comes of age. J Clin Oncol 29(36):4828–4836.  https://doi.org/10.1200/JCO.2011.38.0899CrossRefPubMedPubMedCentralGoogle Scholar
  144. Van Der Merwe PA, Davis SJ (2003) Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol 21:659–684.  https://doi.org/10.1146/annurev.immunol.21.120601.141036CrossRefPubMedGoogle Scholar
  145. Verma N et al (2017) Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations. Clin Exp Immunol 190:1–7.  https://doi.org/10.1111/cei.12997CrossRefPubMedPubMedCentralGoogle Scholar
  146. Vincenti F et al (2010) A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (benefit study). Am J Transplant 10(3):535–546.  https://doi.org/10.1111/j.1600-6143.2009.03005.xCrossRefPubMedGoogle Scholar
  147. Walker LSK (2017) EFIS lecture: understanding the CTLA-4 checkpoint in the maintenance of immune homeostasis. Immunol Lett 184:43–50.  https://doi.org/10.1016/j.imlet.2017.02.007. Elsevier B.V.
  148. Walker LSK, Sansom DM (2015) Confusing signals: recent progress in CTLA-4 biology. Trends Immunol 36(2):63–70.  https://doi.org/10.1016/j.it.2014.12.001. Elsevier
  149. Wang XB et al (2011) CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation. BMC Immunol 12(1):21.  https://doi.org/10.1186/1471-2172-12-21
  150. Ward SG (1996) CD28: a signalling perspective. Biochem J 318:361–377.  https://doi.org/10.1042/bj3180361. Portland Press Limited
  151. Waterhouse P et al (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270(5238):985–988.  https://doi.org/10.1126/science.270.5238.985. New York, N.Y.
  152. Watts TH (2004) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23(1):23–68.  https://doi.org/10.1146/annurev.immunol.23.021704.115839CrossRefGoogle Scholar
  153. Wherry EJ et al (2007) Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27(4):670–684.  https://doi.org/10.1016/j.immuni.2007.09.006CrossRefPubMedGoogle Scholar
  154. Wing K et al (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271–275.  https://doi.org/10.1126/science.1164164CrossRefPubMedGoogle Scholar
  155. Yamaguchi T et al (2013) Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression. Proc Natl Acad Sci USA 110(23):E2116–E2125.  https://doi.org/10.1073/pnas.1307185110
  156. Yang W et al (2017) Dynamic regulation of CD28 conformation and signaling by charged lipids and ions. Nat Struct Mol Biol 24:1081.  https://doi.org/10.1038/nsmb.3489
  157. Yokosuka T et al (2010) Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity 33(3):326–339.  https://doi.org/10.1016/j.immuni.2010.09.006CrossRefPubMedGoogle Scholar
  158. Yoshinaga SK et al (1999) T-cell co-stimulation through B7RP-1 and ICOS. Nature 402(6763):827–832.  https://doi.org/10.1038/45582. Nature Publishing Group
  159. Zhang, YI, Allison JP (1997) Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. Immunology. www.pnas.org. Accessed 12 July 2019
  160. Zhang Q, Vignali DAA (2016) Co-stimulatory and Co-inhibitory pathways in autoimmunity. Immunity 44:1034–1051.  https://doi.org/10.1016/j.immuni.2016.04.017
  161. Zou W, Chen L (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8:467–477.  https://doi.org/10.1038/nri2326

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Molecular Signaling and Cell Death UnitVIB-UGent Center for Inflammation ResearchGhentBelgium
  2. 2.Institutes of Biomedical Sciences, Zhongshan-Xuhui HospitalFudan UniversityShanghaiChina

Personalised recommendations